Dg Shah

Shah who was well networked, understood the IPR, trade, regulatory and drug pricing policies in depth, was a natural leader to lead the Indian pharmaceutical industry.

Pharma body comes up with new guidelines on data integrity

Data reliability or data integrity are often linked to allegations of data falsification or manipulation, which are cited as main reasons by US FDA for pulling up Indian companies as part of its regulatory scrutiny.

IACC Convention: Pharma & the USFDA jigsaw

Watch the interview of DG Shah, Habil Khorakiwala, KG Ananthakrishnan, Nandkumar Chodankar, SK Nanda, Sudhansh Pant to CNBC-TV18‘s Ekta Batra where they spoke about issues that standout in terms of India and America and the pharmaceutical sector.

Here's who competed for the coveted India Healthcare Awards

India is all set to become one of the top economies of the world and Asia‘s next super power. India‘s growing market of 1.2 billion people with an average age of 25 an economy capable of generating a GDP of 8.5% and a middle-class of 250 million people have experts‘ confidence that India will grow rapidly in coming decade.

Pharma pricing policy is bitter pill for biz, public: Shah

DG Shah, secretary-general, Indian Pharmaceutical Alliance explains to CNBC-TV18 that the new pharma pricing adopted by the government would offer less effective drugs to consumers, stifle the growth of research and development in India and stall overseas investment.

Drug cos want market based pricing but may hurt consumers

With GoM set to take a call on framing the drug pricing policy, India's largest association of pharma companies has submitted a study to show the pricing formula should be market based. But critics say this could end up in increasing drug prices reports CNBC-TV18's Archana Shukla.

Compulsory licencing: Should govt tighten norms in pharma?

The Department of Industrial Policy and Promotion (DIPP) had put out a discussion paper dealing with compulsory licenses for the pharmaceutical sector. DG Shah, secretary general, Indian Pharmaceutical Alliance, speaks about the issue.